source
- AstraZeneca proposes $10 billion purchase of Rhythm Pharmaceuticals, sparking possible bidding warAstraZeneca has reportedly made an offer of about $10 billion to buy Rhythm Pharmaceuticals, a company focused on rare obesity disorders. Analysts from at least three research groups say the propo…
- Madrigal’s 2024 MASH drug sparks new wave of diagnosis and personalized treatment approachesThe article argues that the field of metabolic dysfunction‑associated steatohepatitis (MASH) is entering a period of rapid innovation, and that the industry must broaden efforts in diagnosis, monit…